Plain-English translation of NCT07446439 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a medication called to see if it can reduce nausea and vomiting that some people experience when taking GLP-1 receptor agonists (a popular class of weight-loss drugs). The medication will be given twice daily for about 2 weeks to see if it helps manage these side effects better than a placebo.
Weight-loss drugs in this class are very effective but often cause nausea and vomiting that can be difficult for patients to tolerate. Researchers want to find out if this medication can help reduce these side effects so people can stay on their weight-loss treatment more comfortably.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to either take the new medication or a placebo (a pill with no active ingredient) twice daily for about 2 weeks. Half the participants will receive the real medication, and half will receive the placebo, though neither you nor the researchers will know which one you're taking until the study ends. You'll likely have a few clinic visits to check how you're doing and track any changes in your nausea or vomiting.
AI-generated summary from trial data · Jun 5, 2026 · Not medical advice
United States